nach oben

Erschienen in:

01.07.2015 | Original Article

Differences between glioblastomas and primary central nervous system lymphomas in ¹H-magnetic resonance spectroscopy

verfasst von: Hiroyuki Aburano, Fumiaki Ueda, Yuichi Yoshie, Osamu Matsui, Mitsutoshi Nakada, Yutaka Hayashi, Toshifumi Gabata

Erschienen in: Japanese Journal of Radiology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The present study aimed to distinguish between glioblastomas and primary central nervous system lymphomas (PCNSLs) using ¹H-magnetic resonance spectroscopy (MRS), especially glutamate (Glu)/creatine (Cr) and Glu/Glu+glutamine (Gln) ratios.

Materials and methods

A total of 46 patients (31 cases diagnosed with glioblastoma, 15 with PCNSL) were examined by in vivo single-voxel proton ¹H-MRS with a 3-T MR imaging system. Differences in absolute concentration of Cr, choline/Cr, lipid (1.3 ppm)/Cr, Glu+Gln/Cr, Glu/Cr, and Glu/Glu+Gln ratios among groups were evaluated with Mann–Whitney U tests.

Results

PCNSLs [3.408 ± 1.194 (standard deviation)] showed significantly higher Glu/Cr ratios as compared to glioblastomas (2.220 ± 0.942; P = 0.003) [Glu/Cr cutoff ratio of 2.509 showed a sensitivity of 88 % (7/8) and a specificity of 92 % (22/24)], while glioblastomas (0.539 ± 0.098) showed significantly lower Glu/Glu+Gln ratios as compared to PCNSLs (0.728 ± 0.147; P < 0.001) [Glu/Glu+Gln cutoff ratio of 0.558 showed a sensitivity of 69 % (18/26) and a specificity of 100 % (13/13)]. And PCNSLs (1.101 ± 0.387) showed significantly higher Cho/Cr ratios as compared to glioblastomas (0.850 ± 0.465; P = 0.026).

Conclusion

Glu/Cr, Glu/Glu+Gln, and Cho/Cr ratios may be useful in distinguishing between glioblastomas and PCNSLs.

Harting I, Hartmann M, Jost G, Sommer C, Ahmadi R, Heiland S, et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett. 2013;342:163–6.CrossRef

Chawla S, Zhang Y, Wang S, Chaudhary S, Chou C, O’Rourke DM, et al. Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr. 2010;34:836–41.PubMedCrossRef

Braitenberg V, Schüz A. Cortex: statistics and geometry of neuronal connectivity. Berlin: Springer-Verlag; 1998.CrossRef

Agarwal N, Renshaw PF. Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications. AJNR Am J Neuroradiol. 2012;33:595–602.PubMedCrossRef

Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol. 2010;97:11–23.PubMedCrossRef

Lehmann C, Bette S, Engele J. High extracellular glutamate modulates expression of glutamate transporters and glutamine synthetase in cultured astrocytes. Brain Res. 2009;1297:1–8.PubMedCrossRef

Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–9.PubMedCrossRef

Provencher SW. Automatic quantitation of localized in vivo ¹H spectra with LCModel. NMR Biomed. 2001;14:260–4.PubMedCrossRef

Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97–117.PubMedCrossRef

10.

Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol. 1995;16:1593–603.PubMed

11.

Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177–83.PubMedCrossRef

12.

Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol. 2008;29:471–5.PubMedCrossRef

13.

Shigeri Y, Seal RP, Shimamoto K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004;45:250–65.PubMedCrossRef

14.

Pow DV, Robinson SR. Glutamate in some retinal neurons is derived solely from glia. Neuroscience. 1994;60:355–66.PubMedCrossRef

15.

Evan N, Kamel K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther. 2009;8:1791–7.

16.

Ye ZC, Rothstein JD, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci. 1999;19:10767–77.PubMed

17.

Pfund Z, Chugani DC, Juhasz C, Muzik O, Chugani HT, Wilds IB, et al. Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and ¹H magnetic resonance spectroscopy in patients with epilepsy. J Cereb Blood Flow Metab. 2000;20:871–8.PubMedCrossRef

18.

Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008;190:365–9.CrossRef

19.

Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997;10:2–12.PubMedCrossRef

20.

Sijens PE, Oudkerk M, van Dijk P, Levendag PC, Vecht CJ. MR spectroscopy monitoring of changes in Cho peak area and line shape after Gd-contrast administration. Magn Reson Imag. 1998;16:1273–80.CrossRef

21.

Sijens PE, van den Bent MJ, Nowak PJ, van Dijk P, Oudkerk M. ¹H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn Reson Med. 1997;37:222–5.PubMedCrossRef

22.

Murphy PS, Leach MO, Rowland IJ. The effects of paramagnetic contrast agents on metabolite protons in aqueous solution. Phys Med Biol. 2002;47:53–9.

23.

Lima EC, Otaduy MCG, Tsunemi M, Pincerato R, Cardoso EF, Rosemberg S, Aguiar PH, Cerri GG, Leite CC. The effect of paramagnetic contrast in choline peak in patients with glioblastoma multiforme might not be significant. AJNR Am J Neuroradiol. 2013;34:80–4.PubMedCrossRef

24.

Helms G. Analysis of 1.5 Tesla proton MR spectra of human brain using LCModel and an imported basis set. Magn Reson Imag. 1999;17:1211–8.CrossRef

Titel: Differences between glioblastomas and primary central nervous system lymphomas in 1H-magnetic resonance spectroscopy
verfasst von: Hiroyuki Aburano
Fumiaki Ueda
Yuichi Yoshie
Osamu Matsui
Mitsutoshi Nakada
Yutaka Hayashi
Toshifumi Gabata
Publikationsdatum: 01.07.2015
Verlag: Springer Japan
Erschienen in: Japanese Journal of Radiology / Ausgabe 7/2015
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-015-0430-5

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Differences between glioblastomas and primary central nervous system lymphomas in ¹H-magnetic resonance spectroscopy